nach oben

Clinical and Translational Oncology

Erschienen in:

06.07.2019 | Review Article

Altered expression and functional role of ion channels in leukemia: bench to bedside

verfasst von: H. Rafieemehr, A. Samimi, M. Maleki Behzad, M. Ghanavat, S. Shahrabi

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Leukemic cells’ (LCs) survival, proliferation, activation, differentiation, and invasiveness/migration can be mediated through the function of cation and anion channels that are involved in volume regulation, polarization, cytoskeleton, and extracellular matrix reorganization. This study will review the expression of ion channels in LCs and their possible function in leukemia progression. We searched relevant literature by a PubMed (2002–2019) of English-language literature using the terms “ion channels”, “leukemia”, “proliferation”, “differentiation”, “apoptosis”, and “migration”. Altered expression and dysfunction of ion channels can have a strong impact on hematopoietic cell and LCs physiology and signaling, which contributes to the vital processes such as proliferation, differentiation, and apoptosis. Indeed, it can be stated that changing expression of ion channels can affect the onset and progression as well as clinical features and therapeutic responses of leukemia via inducing the maintenance of LCs. Since ion channels are membrane proteins, they can be easily accessible in LCs for understanding their influence on leukemia progression. On the other hand, ion channels can be new potential targets for chemotherapeutic agents, which may open a novel clinical and pharmaceutical field in leukemia therapy.

Jean-Yves LG, Halima O-A, Olivier S, Pierre B, Ahmed A, Christophe V. Voltage-gated ion channels, new targets in anti-cancer research. Recent Pat Anticancer Drug Discov. 2007;2(3):189–202.

Arcangeli A, Becchetti A. Novel perspectives in cancer therapy: targeting ion channels. Drug Resist Updat. 2015;21:11–9.PubMed

Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, Becchetti A. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr Med Chem. 2009;16(1):66–93.PubMed

Turner KL, Sontheimer H. Cl − and K + channels and their role in primary brain tumour biology. Philos Trans R Soc Lond B Biol Sci. 2014;369(1638):20130095.PubMedCentralPubMed

Becchetti A. Ion channels and transporters in cancer. 1. Ion channels and cell proliferation in cancer. Am J Physiol Cell Physiol. 2011;301(2):C255–65.PubMed

Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, Basile V, et al. VEGFR-1 (FLT-1), β1 integrin, and hERG K + channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood. 2007;110(4):1238–50.PubMed

Tefferi A, Vardiman J. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14.PubMed

Arcangeli A, Becchetti A. Complex functional interaction between integrin receptors and ion channels. Trends Cell Biol. 2006;16(12):631–9.PubMed

Kaczmarek LK. Non-conducting functions of voltage-gated ion channels. Nat Rev Neurosci. 2006;7(10):761.PubMed

10.

Arcangeli A, Pillozzi S, Becchetti A. Targeting ion channels in leukemias: a new challenge for treatment. Curr Med Chem. 2012;19(5):683–96.PubMed

11.

Becchetti A, Arcangeli A. Integrins and ion channels in cell migration: implications for neuronal development, wound healing and metastatic spread. Adv Exp Med Biol. 2010;674:107–23.PubMed

12.

Lang F, Föller M, Lang K, Lang P, Ritter M, Gulbins E, et al. Ion channels in cell proliferation and apoptotic cell death. J Membr Biol. 2005;205(3):147–57.PubMed

13.

Prevarskaya N, Skryma R, Shuba Y. Ion channels and the hallmarks of cancer. Trends Mol Med. 2010;16(3):107–21.PubMed

14.

Cuddapah VA, Sontheimer H. Ion channels and transporters in cancer. 2. Ion channels and the control of cancer cell migration. Am J Physiol Cell Physiol. 2011;301(3):C541–9.PubMedCentralPubMed

15.

D’Amico M, Gasparoli L, Arcangeli A. Potassium channels: novel emerging biomarkers and targets for therapy in cancer. Recent Pat Anticancer Drug Discov. 2013;8(1):53–65.PubMed

16.

Saki N, Abroun S, Hagh MF, Asgharei F. Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell J. 2011;13(3):131.PubMedCentralPubMed

17.

Park KS, Pang B, Park SJ, Lee Y-G, Bae J-Y, Park S, et al. Identification and functional characterization of ion channels in CD34 + hematopoietic stem cells from human peripheral blood. Mol Cells. 2011;32(2):181–8.PubMedCentralPubMed

18.

Zhang W, Hirschler-Laszkiewicz I, Tong Q, Conrad K, Sun S-C, Penn L, et al. TRPM2 is an ion channel that modulates hematopoietic cell death through activation of caspases and PARP cleavage. Am J Physiol Cell Physiol. 2006;290(4):C1146–59.PubMed

19.

Li H, Liu L, Guo L, Zhang J, Du W, Li X, et al. HERG K + channel expression in CD34 +/CD38 −/CD123 high cells and primary leukemia cells and analysis of its regulation in leukemia cells. Int J Lab Hematol. 2008;87(4):387.

20.

Li H, Liu L, Guo T, Zhang J, Li X, Du W, et al. Expression and functional role of HERG1, K + channels in leukemic cells and leukemic stem cells. J Huazhong Univ Sci Technol Med Sci. 2007;27(3):257–60.

21.

Urrego D, Tomczak AP, Zahed F, Stühmer W, Pardo LA. Potassium channels in cell cycle and cell proliferation. Philos Trans R Soc Lond B Biol Sci. 2014;369(1638):20130094.PubMedCentralPubMed

22.

Glassmeier G, Hempel K, Wulfsen I, Bauer CK, Schumacher U, Schwarz JR. Inhibition of HERG1 K + channel protein expression decreases cell proliferation of human small cell lung cancer cells. Pflug Arch. 2012;463(2):365–76.

23.

Leanza L, O’Reilly P, Doyle A, Venturini E, Zoratti M, Szegezdi E, et al. Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines. Curr Pharm Des. 2014;20(2):189–200.PubMed

24.

Arcangeli A. Ion channels and transporters in cancer. 3. Ion channels in the tumor cell-microenvironment cross talk. Am J Physiol Cell Physiol. 2011;301(4):C762–71.PubMed

25.

Rafieemehr H, Kheirandish M, Soleimani M. Improving the neuronal differentiation efficiency of umbilical cord blood-derived mesenchymal stem cells cultivated under appropriate conditions. Iran J basic Med Sci. 2015;18(11):1100.PubMedCentralPubMed

26.

Rafieemehr H, Kheirandish M, Soleimani M. Neural differentiation of human umbilical cord blood derived mesenchymal stem cells. Avicenna J Med Biochem. 2016;4(1):e29066.

27.

Ravan AP, Goudarzi F, Rafieemehr H, Bahmani M, Rad F, Jafari M, et al. Human umbilical cord-mesenchymal stem cells conditioned medium attenuates CCl4 induced chronic liver fibrosis. Toxin Rev. 2019;38(3):1–12.

28.

Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, et al. Inhibition of CXCR29 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther. 2006;5(12):3113–21.PubMed

29.

Pillozzi S, Masselli M, De Lorenzo E, Accordi B, Cilia E, Crociani O, et al. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood. 2011;117(3):902–14.PubMed

30.

Liu P, Ma D, Yu Z, Zhe N, Ren M, Wang P, et al. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia. Biomed Pharmacother. 2017;91:21–30.PubMed

31.

Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014;24:71–81.PubMed

32.

Li H, Du YM, Guo L, Jie S, Zhang S, Du W, et al. The role of hERG1 K + channels and a functional link between hERG1 K + channels and SDF-1 in acute leukemic cell migration. Exper Cell Res. 2009;315(13):2256–64.

33.

Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest. 2007;117(4):1049–57.PubMedCentralPubMed

34.

Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, et al. Targeting the leukemia microenvironment by CXCR35 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113(24):6215–24.PubMedCentralPubMed

35.

Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov. 2009;8(12):982–1001.PubMedCentralPubMed

36.

Hemmerlein B, Weseloh RM, de Queiroz MF, Knotgen H, Sanchez A, Rubio ME, et al. Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer. 2006;5:41.PubMedCentralPubMed

37.

Gomez-Varela D, Zwick-Wallasch E, Knotgen H, Sanchez A, Hettmann T, Ossipov D, et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res. 2007;67(15):7343–9.PubMed

38.

Rodriguez-Rasgado JA, Acuna-Macias I, Camacho J. Eag1 channels as potential cancer biomarkers. Sensors (Basel). 2012;12(5):5986–95.PubMedCentralPubMed

39.

Downie BR, Sanchez A, Knotgen H, Contreras-Jurado C, Gymnopoulos M, Weber C, et al. Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. J Biol Chem. 2008;283(52):36234–40.PubMedCentralPubMed

40.

Agarwal JR, Griesinger F, Stuhmer W, Pardo LA. The potassium channel Ether a go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer. 2010;9:18.PubMedCentralPubMed

41.

Lin H, Li Z, Chen C, Luo X, Xiao J, Dong D, et al. Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether a go-go K + channel. PLoS One. 2011;6(5):e20362.PubMedCentralPubMed

42.

Behzad MM, Shahrabi S, Jaseb K, Bertacchini J, Ketabchi N, Saki N. Aberrant DNA methylation in chronic myeloid leukemia: cell fate control, prognosis, and therapeutic response. Biochem Gene. 2018;56(3):149–75.

43.

Leanza L, Venturini E, Kadow S, Carpinteiro A, Gulbins E, Becker KA. Targeting a mitochondrial potassium channel to fight cancer. Cell Calcium. 2015;58(1):131–8.PubMed

44.

Leanza L, Henry B, Sassi N, Zoratti M, Chandy KG, Gulbins E, et al. Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells. EMBO Mol Med. 2012;4(7):577–93.PubMedCentralPubMed

45.

Szabò I, Zoratti M, Gulbins E. Contribution of voltage-gated potassium channels to the regulation of apoptosis. FEBS Lett. 2010;584(10):2049–56.PubMed

46.

Palme D, Misovic M, Schmid E, Klumpp D, Salih HR, Rudner J, et al. Kv.34 potassium channel-mediated electrosignaling controls cell cycle and survival of irradiated leukemia cells. Pflug Arch. 2013;465(8):1209–21.

47.

Szabo I, Trentin L, Trimarco V, Semenzato G, Leanza L. Biophysical characterization and expression analysis of Kv1.3 potassium channel in primary human leukemic B cells. Cell Physiol Biochem. 2015;37(3):965–78.PubMed

48.

Roskoski R Jr. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res. 2012;66(2):105–43.PubMed

49.

Nguyen W, Howard BL, Neale DS, Thompson PE, White PJ, Wulff H, et al. Use of Kv1.3 blockers for inflammatory skin conditions. Curr Med Chem. 2010;17(26):2882–96.PubMedCentralPubMed

50.

Grossinger EM, Weiss L, Zierler S, Rebhandl S, Krenn PW, Hinterseer E, et al. Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade. Leukemia. 2014;28(4):954–8.PubMed

51.

Wang J, Xu YQ, Liang YY, Gongora R, Warnock DG, Ma HP. An intermediate-conductance Ca(2 +)-activated K (+) channel mediates B lymphoma cell cycle progression induced by serum. Pflug Arch. 2007;454(6):945–56.

52.

Cid LP, Roa-Rojas HA, Niemeyer MI, Gonzalez W, Araki M, Araki K, et al. TASK-2: a K2P K(+) channel with complex regulation and diverse physiological functions. Front Physiol. 2013;4:198.PubMedCentralPubMed

53.

Enyedi P, Czirjak G. Molecular background of leak K + currents: two-pore domain potassium channels. Physiol Rev. 2010;90(2):559–605.PubMed

54.

Liu H, Enyeart JA, Enyeart JJ. Potent inhibition of native TREK-1 K + channels by selected dihydropyridine Ca2 + channel antagonists. J Pharmacol Exp Ther. 2007;323(1):39–48.PubMed

55.

Borsotto M, Veyssiere J, Maati MOH, Devader C, Mazella J, Heurteaux C. Targeting two-pore domain K(+) channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept. Br J Pharmacol. 2015;172(3):771–84.PubMed

56.

Meuth SG, Bittner S, Meuth P, Simon OJ, Budde T, Wiendl H. TWIK-related acid-sensitive K + channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions. J Biol Chem. 2008;283(21):14559–70.PubMed

57.

Pottosin II, Bonales-Alatorre E, Valencia-Cruz G, Mendoza-Magaña ML, Dobrovinskaya OR. TRESK-like potassium channels in leukemic T cells. Pflug Arch. 2008;456(6):1037–48.

58.

Sánchez-Miguel DS, García-Dolores F, Flores-Márquez MR, Delgado-Enciso I, Pottosin I, Dobrovinskaya O. TRESK potassium channel in human T lymphoblasts. Biochem Biophys Res Commun. 2013;434(2):273–9.PubMed

59.

Es-Salah-Lamoureux Z, Steele DF, Fedida D. Research into the therapeutic roles of two-pore-domain potassium channels. Trends Pharmacol Sci. 2010;31(12):587–95.PubMed

60.

Semenova SB, Vassilieva IO, Fomina AF, Runov AL, Negulyaev YA. Endogenous expression of TRPV5 and TRPV6 calcium channels in human leukemia K562 cells. Am J Physiol Cell Physiol. 2009;296(5):C1098–104.PubMed

61.

Feske S, Skolnik EY, Prakriya M. Ion channels and transporters in lymphocyte function and immunity. Nat Rev Immunol. 2012;12(7):532.PubMedCentralPubMed

62.

Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem. 2012;287(38):31666–73.PubMedCentralPubMed

63.

Lehen’Kyi V, Flourakis M, Skryma R, Prevarskaya N. TRPV6 channel controls prostate cancer cell proliferation via Ca 2 +/NFAT-dependent pathways. Oncogene. 2007;26(52):7380.PubMed

64.

Heise N, Palme D, Misovic M, Koka S, Rudner J, Lang F, et al. Non-selective cation channel-mediated Ca2 + -entry and activation of Ca2 +/calmodulin-dependent kinase II contribute to G2/M cell cycle arrest and survival of irradiated leukemia cells. Cell Physiol Biochem. 2010;26(4–5):597–608.PubMed

65.

Vassilieva IO, Tomilin VN, Marakhova II, Shatrova AN, Negulyaev YA, Semenova SB. Expression of transient receptor potential vanilloid channels TRPV5 and TRPV6 in human blood lymphocytes and Jurkat leukemia T cells. J Membr Biol. 2013;246(2):131–40.PubMed

66.

Morelli BM, Liberati S, Amantini C, Nabiss M, Santoni M, Farfariello V, et al. Expression and function of the transient receptor potential ion channel family in the hematologic malignancies. Curr Mol Pharmacol. 2013;6(3):137–48.PubMed

67.

Feng W, Wang L, Zheng G. Expression and function of P2 receptors in hematopoietic stem and progenitor cells. Stem Cell Investig. 2015;30(2):14.

68.

Guven Maiorov E, Keskin O, Hatirnaz Ng O, Ozbek U, Gursoy A. Identification of interconnected markers for T-cell acute lymphoblastic leukemia. Biomed Res Int. 2013;2013:210253.PubMedCentral

69.

Roger S, Potier M, Vandier C, Besson P, Le Guennec J-Y. Voltage-gated sodium channels: new targets in cancer therapy? Curr Pharm Des. 2006;12(28):3681–95.PubMed

70.

Fraser SP, Diss JK, Lloyd LJ, Pani F, Chioni A-M, George AJ, et al. T-lymphocyte invasiveness: control by voltage-gated Na + channel activity. FEBS Lett. 2004;569(1–3):191–4.PubMed

71.

Sudarikova A, Vassilieva I, Morachevskaya E, Negulyaev YA. Molecular and functional identification of sodium channels in K562 cells. Cell Tissue Biol. 2012;6(5–6):435–41.

72.

Sudarikova AV, Tsaplina OA, Chubinskiy-Nadezhdin VI, Morachevskaya EA, Negulyaev YA. Amiloride-insensitive sodium channels are directly regulated by actin cytoskeleton dynamics in human lymphoma cells. Biochem Biophys Res Commun. 2015;461(1):54–8.PubMed

73.

Fraser SP, Ozerlat-Gunduz I, Brackenbury WJ, Fitzgerald EM, Campbell TM, Coombes RC, et al. Regulation of voltage-gated sodium channel expression in cancer: hormones, growth factors and auto-regulation. Philos Trans R Soc Lond B Biol Sci. 2014;369(1638):20130105.PubMedCentralPubMed

74.

Hesselink JMK. Moving targets in sodium channel blocker development: the case of raxatrigine: from a central NaV1. 3 blocker via a peripheral NaV1. 7 blocker to a less selective sodium channel blocker. J Med Ther. 2017;1(1):1–3.

75.

Luiz AP, Wood JN. Sodium channels in pain and cancer: new therapeutic opportunities. Adv Pharmacol. 2016;75:153–78.PubMed

76.

Jensen MK, Sakakura T, Abe Y, Takamori H, Takasuna K, Tsurubuchi Y, et al. Use and state dependent Nav1. 5 blockers on QPatch X and in vivo assays. J Pharmacol Toxicol Methods. 2011;1(64):e8.

77.

Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov. 2009;8(2):153.PubMed

78.

Cao G, Zuo W, Fan A, Zhang H, Yang L, Zhu L, et al. Volume-sensitive chloride channels are involved in maintenance of basal cell volume in human acute lymphoblastic leukemia cells. J Membr Biol. 2011;240(2):111–9.PubMed

79.

Jiang B, Hattori N, Liu B, Nakayama Y, Kitagawa K, Inagaki C. Suppression of cell proliferation with induction of p21 by Cl⁻ channel blockers in human leukemic cells. Eur J Pharmacol. 2004;488(1–3):27–34.PubMed

80.

Kasinathan RS, Föller M, Lang C, Koka S, Lang F, Huber SM. Oxidation induces ClC-3-dependent anion channels in human leukaemia cells. FEBS Lett. 2007;581(28):5407–12.PubMed

81.

Renaudo A, L’Hoste S, Guizouarn H, Borgèse F, Soriani O. Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl–channels. J Biol Chem. 2007;282(4):2259–67.PubMed

82.

Zuo W, Zhu L, Bai Z, Zhang H, Mao J, Chen L, et al. Chloride channels involve in hydrogen peroxide-induced apoptosis of PC12 cells. Biochem Biophys Res Commun. 2009;387(4):666–70.PubMed

83.

de Tassigny ADA, Berdeaux A, Souktani R, Henry P, Ghaleh B. The volume-sensitive chloride channel inhibitors prevent both contractile dysfunction and apoptosis induced by doxorubicin through PI3kinase, Akt and Erk 1/2. Eur J Heart Fail. 2008;10(1):39–46.

84.

Pedersen SF, Hoffmann EK, Novak I. Cell volume regulation in epithelial physiology and cancer. Front Physiol. 2013;4:233.PubMedCentralPubMed

85.

Chae YK, Kang SK, Kim MS, Woo J, Lee J, Chang S, et al. Human AQP5 plays a role in the progression of chronic myelogenous leukemia (CML). PLoS One. 2008;3(7):e2594.PubMedCentralPubMed

86.

Lowinus T, Heidel FH, Bose T, Nimmagadda SC, Schnöder T, Cammann C, et al. Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of K v 1.3 potassium channels, AKT and ERK1/2 signaling. Cell Commun Signal. 2019;17(1):5.PubMedCentralPubMed

87.

Rahm AK, Gierten J, Kisselbach J, Staudacher I, Staudacher K, Schweizer PA, et al. PKC-dependent activation of human K2P18. 1 K + channels. Br J Pharmacol. 2012;166(2):764–73.PubMedCentralPubMed

88.

Chong J-H, Zheng G-G, Ma Y-Y, Zhang H-Y, Nie K, Lin Y-M, et al. The hyposensitive N187D P2X7 mutant promotes malignant progression in nude mice. J Biol Chem. 2010;285(46):36179–87.PubMedCentralPubMed

89.

Gulbins E, Sassi N, Grassme H, Zoratti M, Szabo I. Role of Kv.13 mitochondrial potassium channel in apoptotic signalling in lymphocytes. Biochim Biophys Acta. 2010;1797(6–7):1251–9.PubMed

Titel: Altered expression and functional role of ion channels in leukemia: bench to bedside
verfasst von: H. Rafieemehr
A. Samimi
M. Maleki Behzad
M. Ghanavat
S. Shahrabi
Publikationsdatum: 06.07.2019
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 3/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-019-02147-2

Springer Medizin

Altered expression and functional role of ion channels in leukemia: bench to bedside

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab

Long noncoding RNA CASC2c inhibited cell proliferation in hepatocellular carcinoma by inactivated ERK1/2 and Wnt/β-catenin signaling pathway

Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with HBV-associated hepatocellular carcinoma after curative hepatectomy

Influence of the technique and comorbidities in hypofractionated radiotherapy for prostate cancer

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

Clinical significance of epithelial–mesenchymal transition-related markers expression in the micrometastatic sentinel lymph node of NSCLC

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie